Abstract:Alcohol-associated hepatitis (AH) is associated with increased short-term mortality in the presence of infections and rapid onset of extrahepatic organ failure driven by intestinal dysbiosis. [ 1 ] Deleterious modifications of the gut microbiota (GM) which include bacteria, fungi, and viral groups in the presence of alcohol are well documented across multiple studies globally. [ 2 ] Gut microbiota contributes to individual susceptibility to alcohol-related liver disease (ALD) and AH through detrimental changes to immune signaling, functional metabolism, and the gut–brain axis. [ 3 ] Specific bacterial taxa have been shown to affect the promotion, progression, and clinical events associated with ALD and AH. For example, in the presence of alcohol, pathogenic bacteria, such as Acinetobacter baumannii enhance their virulence. Alcohol use reduces bacterial diversity, decreases the abundance of beneficial Bacteroidetes, and increases that of pathogenic Proteobacteria, as demonstrated by a significant decrease in Ruminococcaceae and an increase in both Lachnospiraceae and Enterobacteriaceae. [ 4 , 5 ] Alcohol-induced GM dysbiosis leads to liver damage owing to the proliferation of harmful microorganisms that produce exotoxins. One such exotoxin, cytolysin, secreted by Enterococcus faecalis , can directly harm hepatocytes. A higher presence of cytolysin-positive Enterococcus faecalis correlates with greater severity of liver disease and elevated mortality rates in patients with AH. [ 6 ] Specific GM, their interactions, and metabolites are associated with complications of AH and the corresponding treatment outcomes. [ 7 ] Similarly, fungal dysbiosis and fungal metabolites affect the severity of AH. The burgeoning field of research on fungal dysbiosis and proliferation of specific fungal species in ALD has revealed significant findings. Elevated serum levels of anti- Saccharomyces cerevisiae immunoglobulin G antibodies, which indicate a systemic immune response to fungi and their byproducts, are observed in patients with alcohol use disorder and ALD. In patients with AH, heightened serum anti- Saccharomyces cerevisiae immunoglobulin G antibodies levels are associated with increased mortality. Additionally, a higher relative abundance of specific fungal species, such as Candida albicans and Malassezia restricta in the gut, correlates with more severe liver injury and increased mortality in ALD patients. [ 8–10 ] Preliminary studies have shown that patients with ALD and AH can benefit from GM modulation. Clinical trials have explored the use of fecal microbiota transplantation (FMT) to alter the gut microbiome of patients with AH. Studies have demonstrated that AH patients who received FMT from healthy donors exhibited lower rates of alcohol relapse, infections, or hospitalizations; higher rates of resolution of hepatic encephalopathy and ascites; and improved survival in both the short and long term when compared to standard medical care, including pentoxifylline therapy. [ 11–13 ] Another randomized controlled study included 120 patients with AH who received either prednisolone or a healthy donor FMT. Patients receiving FMT had better 90-day survival rates and a reduced incidence of infections compared to those receiving prednisolone. [ 14 ] Probiotics have been shown to improve clinical outcomes in alcohol-associated cirrhosis, and foundational evidence supports their positive effects on GM. Preliminary evidence also supports the beneficial effects of probiotic therapy on GM in AH. [ 15 , 16 ] Nonetheless, the validated and replicated benefits of probiotic therapy and their impact on survival in the context of GM modulation remain unknown. Similarly, probiotic therapy-related modifications within fungal communities, fungal–bacterial interactions, and associated clinical outcomes in AH are enigmatic. We aimed to study the clinical outcomes and GM changes in AH patients receiving high-dose probiotic infusion (HDPI) compared to corticosteroid therapy (CST). Additionally, survival outcomes compared with matched patients undergoing healthy donor FMT were also analyzed. We also studied mycobiome (fungal) community changes and their interactions among patients with AH in the context of HDPI and CST therapies.

Recent alcohol intake impacts microbiota in adult burn patients

7 Alcohol Use Acuity and Burn Mortality: A Ten-Year Retrospective Analysis

The effects of cigarettes and alcohol on intestinal microbiota in healthy men

Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice

Alcohol or Gut Microbiota: Who Is the Guilty?

Diet High in Alcohol Impacts the Gut Microbiota and Associated Metabolome (P08-134-19)

Adverse clinical outcomes associated with elevated blood alcohol levels at the time of burn injury

Intoxication by Intraperitoneal Injection or Oral Gavage Equally Potentiates Postburn Organ Damage and Inflammation

Burn Injury Leads to Increase in Relative Abundance of Opportunistic Pathogens in the Rat Gastrointestinal Microbiome

Dysregulated meta-organismal metabolism of aromatic amino acids in alcohol-associated liver disease

Abstract 2214: Impacts of habitual and recent alcohol intake on gut microbiome diversity and composition among Black Americans

Protective effects of PX478 on gut barrier in a mouse model of ethanol and burn injury

Evidence that keratinocyte microvesicle particles carrying Platelet-activating factor mediate the widespread multi-organ damage associated with intoxicated thermal burn injury

Alcohol, Intestinal Bacterial Growth, Intestinal Permeability to Endotoxin, and Medical Consequences: Summary of a Symposium

IL-27 Promotes Intestinal Barrier Integrity following Ethanol Intoxication and Burn Injury

Acute alcohol consumption increases systemic endotoxin bioactivity for days in healthy volunteers—with reduced intestinal barrier loss in female

Chronic binge drinking-induced susceptibility to colonic inflammation is microbiome-dependent

The Role of Gut Bacteria and Fungi in Alcohol-Associated Liver Disease

Impact of Metabolic Risk Factors on the Severity and Outcome of Patients with Alcohol-Associated Acute-on-chronic Liver Failure.

Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis

Clinical outcomes and associated bacterial and fungal microbiota changes after high dose probiotic therapy for severe alcohol-associated hepatitis: An observational study